Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia : A systematic review

Health Technology Assessment

Volumn 14, Issue 54, 2010, Pages 1-172

  Ashfaq, K ^a   Yahaya, I ^a   Hyde, C ^a   Andronis, L ^a   Barton, P ^a   Bayliss, S ^a   Chen, Y F ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; INTERLEUKIN 2; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW PURGING; CANCER CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG MEGADOSE; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFORMATION RETRIEVAL; LEUKEMIA REMISSION; LOW DRUG DOSE; MEDICAL DECISION MAKING; META ANALYSIS; MYELOABLATIVE CONDITIONING; NATIONAL HEALTH SERVICE; NEUTROPENIA; PNEUMONIA; PROMYELOCYTIC LEUKEMIA; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SEPTICEMIA; SIBLING; SURVIVAL TIME; SYSTEMATIC REVIEW; T CELL DEPLETION; THROMBOCYTOPENIA; UNITED KINGDOM;

EID: 78650100630     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta14540     Document Type: Review

References (312)

1. Cancer Research UK. CancerStats key facts-leukaemia. URL: http://info.cancerresearchuk.org/cancerstats/types/leukaemia/index.htm (accessed 18 January 2010).
2. Cancer Research UK. Latest UK cancer incidence and mortality summary-numbers. URL: http://info.cancerresearchuk.org/cancerstats/incidence/index.htm (accessed 18 January 2010).
3. Hoffbrand AV, Pettit JE, Moss PAH. Essential haematology, 4th edition. Oxford: Blackwell Publishing; 2001.
4. Mohty M, Nagler A, Killmann NM. Reducedintensity conditioning allogeneic stem cell transplantation: hype, reality or time for a rethink? Leukemia 2006;20:1653-4.
5. Kernan NA, Bordignon C, Heller G, Cunningham I, Castro-Malaspina H, Shank B, et al. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia. I. Analysis of risk factors and results of secondary transplants. Blood 1989;74:2227-36.
6. Estey E, Döhner H. Acute myeloid leukaemia. Lancet 2006;368:1894-907.
7. Johnson PW, Simnett SJ, Sweetenham JW, Morgan GJ, Stewart LA. Bone marrow and peripheral blood stem cell transplantation for malignancy: a review. Health Technol Assess 1998;2(8).
8. Wheatley K. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? A statistician's view. Br J Haematol 2002;118:351-6.
9. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decisionanalytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006;24:355-71.
10. Abosoudah I, Vigeveno R, Stobart K, Weitzman S. Stem cell transplantation for acute myelocytic leukaemia in paediatric patients in first remission. Cochrane Database Syst Rev Protocols 2007;3.
11. Naumann F, Kruse E, Weingart O, Bohlius J, Hübel K, Herrmann-Frank A, et al. Autologous stem cell transplantation vs chemotherapy in adult acutelymphocytic leukaemia. Cochrane Database Syst Rev Protocols 2007;4.
12. Institut für Qualitaet und Wirtschaftlichkeit im Gesundheitswesen. Stem cell transplantation in adults with acute lymphoblastic leukaemia (ALL) or acute myeloid leukaemia (AML). Cologne: IQWiG; 2007.
13. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2005;11:823-61.
14. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 2006;12:1-30.
15. Visani G, Olivieri A, Malagola M, Brunori M, Piccaluga PP, Capelli D, et al. Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine. Leuk Lymphoma 2006;47:1091-102.
16. Oliansky DM, Rizzo JD, Aplan PD, Arceci RJ, Leone L, Ravindranath Y, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2007;13:1-25.
17. Oliansky DM, Appelbaum F, Cassileth PA, Keating A, Kerr J, Nieto Y, et al. the role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 2008;14:137-80.
18. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005;103:1652-8.
19. Yanada M, Matsuo K, Suzuki T, Naoe T. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 2006;106:2657-63
20. Nathan PC, Sung L, Crump M, Reyene J. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst 2004;96:38-45.
21. Levi I, Grotto I, Yerushalmi R, Ben-Bassat I, Shpilberg O. Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leuk Res 2004;28:605-12.
22. Cornelissen JJ, Van Putten WLJ, Verdonck LF, Theobald M, Jacky E, Daenen SMG, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007;109:3658-66.
23. Bleakley M, Lau L, Shaw PJ, Kaufman A. Bone marrow transplantation for paediatric AML in first remision: a systematic review and meta-analysis. Bone Marrow Transplant 2002;29:843-52.
24. Schaich M, Schlenk RF, Al-Ali HK, Dohner H, Ganser A, Heil G, et al. Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. Haematologica 2007;92:763-70.
25. Schlenk RF, Benner A, Krauter J, Buchner T, Sauerland C, Ehninger G, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German acute myeloid leukemia intergroup. J Clin Oncol 2004;22:3741-50.
26. Orsi C, Bartolozzi B, Messori A, Bosi A. Eventfree survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantation. Bone Marrow Transplant 2007;40:643-9.
27. Chalmers TC, Smith H, Jr, Blackburn B, Silverman B, Schroeder B, Reitman D, et al. A method for assesing the quality of a randomized control trial. Control Clin Trials 1981;2:31-49.
28. Harbour R, Miller J. A new system for grading recommendations in evidence-based guidelines. BMJ 2001;323:334-6.
29. Powles RL, Clink HM, Bandini G, Watson JG, Spence D, Jameson B, et al. The place of bone marrow transplantation in acute myelogenous leukaemia. Lancet 1980;1:1047-50.
30. Appelbaum FR, Fisher LD, Thomas ED. Chemotherapy vs marrow transplantation for adults with acute nonlymphocytic leukemia: a five year follow-up. Blood 1988;72:179-84.
31. Champlin RE, Ho WG, Gale RP, Winston D, Selch M, Mitsuyasu R, et al. Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med 1985;102:285-91.
32. Hewlett J, Kopecky KJ, Head D, Eyre HJ, Elias L, Kingsbury L, et al. A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): a Southwest Oncology Group study. Leukemia 1995;9:562-9.
33. Conde E, Iriondo A, Rayón C, Richard C, Fanjul E, Garijo J, et al. Allogeneic bone marrow transplantation versus intensification chemotheraphy for acute myelogenous leukaemia in first remission: a prospective controlled trial. Br J Haematol 1988;68:219-26.
34. Schiller GJ, Nimer SD, Territo MC, Ho WG, Champlin RE, Gajewski JL. Bone marrow transplantation versus high-dose cytarbine based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol 1992;10:41-6.
35. Labar B, Mrsic M, Bogdanic V, Radman I, Nemet D. Chemotherapy versus bone marrow transplantation in adults with acute myelogenous leukemia. Exp Hematol 1991;19:A448.
36. Cassileth PA, Harrington DP, Hines JD, Oken MM, Mazza JJ, McGlave P, et al. Comparison of postremission therapies in adult acute myeloid leukemia: preliminary analysis of an ECOG study. Eastern Cooperative Oncology Group. Hamatol Bluttransfus 1990;33:627-70.
37. Archimbaud E, Thomas X, Michallet M, Jaubert J, Troncy J, Guyotat D, et al. Prospective genetically randomized comparison between intensive post-induction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. J Clin Oncol 1994;12:262-7.
38. Dinsmore R, Shank B, Kapoor N, Teitelbaum HD, Kirkpatrick D, Clarkson B, et al. A randomized trial of marrow transplantation (BMT) vs chemotherapy (CT) maintenance for actue myelogenous leukemia in first remission: preliminary results. Exp Hematol 1987;15:215.
39. Burnett AK, Goldstone AH, Stevens RF, Hann IM, Rees JK, Wheatley K, et al. The role of BMT in addition to intensive chemotherapy in AML infirst CR: results of the MRC AML-10 trial. Blood 1994;84(Suppl. 1):252a.
40. Reiffers J, Gaspard MH, Maraninchi D, Michallet M, Marit G, Stoppa AM. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukemia in first remission: a prospective controlled trial. Br J Haematol 1989;72:57-63.
41. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995;332:217-23.
42. Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D, et al. Autologogous stem cell transplantation versus chemotherapy for adult patients with acute myeloid leukemia in first remission: the BGMT Group experience. Nouv Rev Fr Hematol 1993;35:17-19.
43. Harousseau JL, Cahn JY, Pignon B, Witz F, Delain M, Lioure B, et al. Autologous bone marrow transplantation (ABMT) versus intensive consolidation chemotherapy (ICC) as post remission therapy in adult acute myeloblastic leukemia (AML): final analysis of the GOELAM randomized study. Proc Annu Meet Am Soc Clin Oncol 1996;15:A1051.
44. Hubner G, Link H, Schonrock Nabulsi P, Wandt H, Gramatzki M, Loffler B, et al. Intensive postremission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group. Med Klin 1996;91(Suppl. 3):26-32.
45. Heil G, Krauter J, Raghavachar A, Bergmann L, Hoelzer D, Fiedler W, et al. Risk-adapted induction and consolidation therapy in adults with de novo AML aged 60 years: results of a prospective multicenter trial. Ann Hematol 2004;83:336-44.
46. Schaich M, Ritter M, Illmer T, Lisske P, Thiede C, Schakel U, et al. Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. Br J Haematol 2001;112:300-7.
47. Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, et al. Risk adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia 2003;17:1521-8.
48. Schlenk RF, Dohner H. Risk adapted therapy of AML: the AMLSG ULM experience. Ann Hematol 2004;83(Suppl. 1):S49.
49. Buchner T, Hiddemann W, Berdel WE, Wormann B, Schoch C, Fonatsch C, et al. 6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML cooperative group. J Clin Oncol 2003;21:4496-504.
50. Buchner T, Hiddemann W, Berdel WE, Wörmann B, Haferlach T, Schoch C, et al. Upfront randomized TAD-HAM vs HAM-HAM induction, G-CSF priming vs no G-CSF, and prolonged maintenance vs autologous transplantation in de novo AML, secondary AML and high risk MDS and their subgroups according to cytogenetics and LDH: interim analysis. Blood 2002;100(Suppl.):345a.
51. Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D, et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 1996;10:1874-82.
52. Keating S, de Witte T, Suciu S, Willemze R, Hayat M, Labar B, et al. The influence of HLAmatched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. Br J Haematol 1998;102:1344-53.
53. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-83.
54. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JHK, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002;118(2):385-400.
55. Suciu S, Mandelli F, De WT, Zittoun R, Gallo E, Labar B, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloidleukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/ GIMEMA AML-10 trial. Blood 2003;102:1232-40.
56. Ferrant A, Doyen C, Delannoy A, Cornu G, Martiat P, Latinne D. Allogeneic or autologous bone marrow transplantation for acute non-lymphocytic leukemia in first remission. Bone Marrow Transplant 1991;7:303-9.
57. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1997;90:2978-86.
58. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998;339:1649-56.
59. Burnett AK, Goldstone AH, Stevens RMF, Hann IM, Rees JKH, Gray RG, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet 1998;351:700-8.
60. Tsimberidou A-M, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T, et al. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 2003;97:1721-31.
61. Jourdan E, Boiron J-M, Dastugue N, Vey N, Marit G, Rigal-Huguet F, et al. Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol 2005;23:7676-84.
62. Gale RP, Büchner T, Zhang MJ, Heinecke A, Champlin RE, Dicke KA, et al. HLA- identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission. Leukemia 1996;10:1687-91.
63. Cassileth PA, Anderson JW, Bennett JM, Harrington DP, Hines JD, Lazarus HM, et al. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group. Leukemia 1992;6(Suppl. 2):116-19.
64. Willemze R, Fibbe WE, Kluin-Nelemans JC, Falkenburg JH, Richel DJ, Peters WG, et al. Bone marrow transplantation or chemotherapy as postremission treatment of adult acute myelogenous leukemia. Ann Hematol 1991;62:59-63.
65. Mohty M, de Lavallade H, Ladaique P, Faucher C, Vey N, Coso D, et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 2005;19:916-20.
66. Breems DA, Boogaerts MA, Dekker AW, Van Putten WLJ, Sonneveld P, Huijgens PC, et al. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol 2005;128:59-65.
67. Miggiano MC, Gherlinzoni F, Rosti G, Bandini G, Visani G, Fiacchini M, et al. Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia. Leukemia 1996;10:402-9.
68. Rohatiner AZ, Bassan R, Raimondi R, Amess JA, Arnott S, Personen A, et al. High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia. Ann Oncol 2000;11:1007-15.
69. Bassan R, Raimondi R, Lerede T, D'emilio A, Buelli M, Borleri G, et al. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia. Haematologia 1998;83:627-35.
70. Gale RP, Horowitz M, Rees JK, Gray RG, Oken MM, Estey EH. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia 1996;10:13-19.
71. Gale RP, Rees JKH, Gray RG, Horowitz MM. Is chemotherapy or transplant better in acute myelogenous leukemia (AML) in second remission? Exp Hematol 1991;19:572.
72. Nesbit ME, Buckley JD, Feig S, Anderson JR, Lampkin B, Bernstein ID. Chemotherapy for inductionof remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the children's Cancer Group. J Clin Oncol 1994;12:127-35.
73. Dahl GV, Kalwinsky DK, Mirro J, Look AT, Pui C-H, Murphy SB. Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphocytic leukemia in first remission. J Clin Oncol 1990;8:295-303.
74. Wells RJ, Woods WG, Buckley JD, Odom LF, Benjamin D, Bernstein ID. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Children's Cancer Group study. J Clin Oncol 1994;12:2367-77.
75. Michel G, Leverger G, Leblanc T, Nelken B, Baruchel A, Landman-Parker J, et al. Allogeneic bone marrow transplantation vs aggressive postremission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology. Bone Marrow Transplant 1996;17:191-6.
76. Amadori S, Testi AM, Arico M, Comelli A, Giuliano M, Madon E. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Italian Association of Hematology and Pediatric Oncology Cooperative Group. J Clin Oncol 1993;11:1046-54.
77. Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 1996;334:1428-34.
78. Woods W, Kobrinsky N, Buckley J, Lee JW, Sanders J, Neudorf S, et al. Timed-sequential induction therapy improves post-remission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 1996;87:4979-89.
79. Woods WG, Neudorf S, Gold S, Sanders J, Kobrinsky N, Barnard D. Aggresive post-remission (REM) chemotherapy is better than autologous bone marrow transplantation (BMT) and allogeneic BMT is superior to both in children with acute myeloid leukemia (AML). Am Soc Clin Oncol 1996;15:A1091.
80. Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol 1998;101:130-40.
81. Shaw P, Bergin M, Burgess M, Dalla Pozza L, Kellie SJ, Rowell G, et al. Childhood acute myeloid leukemia: outcome in a single centre using chemotherapy and consolidation with busulphan/cyclophosphamide for bone marrow transplantation. J Clin Oncol 1994;12:2138-45.
82. Alonzo TA, Wells RJ, Woods WG, Lange B, Gerbing RB, Buxton AB, et al. Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era. Leukemia 2005;19:965-70.
83. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer Group. Blood 2001;97:56-62.
84. Pession A, Rondelli R, Basso G, Rizzari C, Testi AM, Fagioli F, et al. Treatment and long-term results in children with acute myeloid leukaemia treated accordingto the AIEOP AML protocols. Leukemia 2005;19:2043-53.
85. Perel Y, Auvrignon A, Leblanc T, Michel G, Reguerre Y, Vannier J-P, et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit-multicenter studies of the French LAME (Leucemie Aigue Myeloblastique Enfant) Cooperative Group. Leukemia 2005;19:2082-9.
86. Lie S, Abrahamsson J, Clauen N, Forestier E, Hasle H, Hovi L, et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. Br J Haematol 2003;122:217-25.
87. Entz-Werle N, Suciu S, van der Werff ten Bosch, Vilmer E, Bertrand Y, Benoit Y, et al. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia 2005;19:2072-81.
88. Liang D-C, Chang T-T, Lin K-H, Lin D-T, Lu M-Y, Chen S-H, et al. Improved treatment results for childhood acute myeloid leukemia in Taiwan. Leukemia 2006;20:136-41.
89. Lange BJ, Dinndorf P, Smith FO, Arndt C, Barnard D, Feig S, et al. Pilot study of idarubicinbased intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941. J Clin Oncol 2004;22:150-6.
90. Wells R, Adams M. Mitoxantrone and cytarabine induction, high-dose cytarabine and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group study 2951. J Clin Oncol 2003;21:2940-7.
91. Proctor SJ, Hamilton PJ, Taylor P, Carey P, Hargrave S, Evans RG. A comparative study of combination chemotherapy versus marrow transplant in first remission in adult acute lymphoblastic leukaemia. Br J Haematol 1988;69:35-9.
92. Forman SJ, Blume KG. Marrow transplantation versus chemotherapy for adult patients with acute lymphoblastic leukemia: results of a clinical study. Transplant Proc 1991;23:1713-14.
93. Fiere D, Archimbaud E, Extra JM, Marty M, David B, Witz F. Calculation of direct standard costs in the evaluation of new technologies: application to the treatment of acute myeloblastic leukemias. Hamatol Bluttransfus 1987;30:125-9.
94. Mrsic M, Nemet D, Labar B, Bogdanic V, Radman I, Zupancic-Salek S. Chemotherapy versus allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia. Transplant Proc 1993;25:1268-70.
95. Mrsic M, Nemet D, Labar B, Bogdanic V, Radman I, Zupancic-Salek S. Chemotherapy versus allogeneic bone marrow transplantation in adults with acute lymphoblastic leukaemia. Proceedings of the 18th European Group for Blood and Marrow Transplantation Meeting, Stockholm, Sweden, 31 May to 3 June 1992.
96. Sebban C, Lepage E, Vernant JP. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. J Clin Oncol 1994;12:2580-7.
97. Fiere D, Sebban C, Vernant J, Witz F, Rigal H, Bouchiex C, et al. Long term results of chemotherapy, allogeneic or autologous bone marrow transplantation (BMT) as post remission therapy in adult acute lymphoblastic leukemia (ALL) for patients included in a prospective multicentric trial (LALA 87). Blood 1994;84:251a.
98. Zander A, Keating M, Dicke M, Dixon D, Pierce S, Jagannath S. A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission. J Clin Oncol 1988;6:1548-57.
99. Zhang MJ, Hoelzer D, Horowitz M. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. Ann Intern Med 1995;123:428-31.
100. Messerer D, Neiss A, Horowitz MM, Hoelzer D, Gale RP. Comparison of chemotherapy and bone marrow transplants using two independent clinical databases. J Clin Epidemiol 1994;47:1119-26.
101. Messerer D, Neiss A, Aydemir U. How can diseasefree survival of adult ALL patients with or without transplants be compared? Oncologie 1991;14:53-5.
102. Tamura S, Takemoto Y, Kanamaru A. Comparison of the survivals between bone marrow transplantation and chemotherapy for acute leukemia in first remission - a Japanese single institution study. Leuk Lymphoma 1992;8:361-4.
103. Fiere D, Broustet A, Leblond V, Maraninchi D, Castaigne S, Flesch M. Comparison of chemotherapy and autologous and allogeneic transplantation as postinduction regimen in adult acute lymphoblastic leukemia: a preliminary multicentric study. Hamatol Bluttransfus 1990;33:9-12.
104. Richards SM, Bailey C, Chessells J, Durrant H, Prentice G. Bone marrow transplant (BMT) for high-risk childhood and adult ALL in first remission compared with chemotherapy. Proc Eur Haematol 1996;24:A555.
105. Bernasconi C, Lazzarino M, Morra E, Alessandrino EP, Pagnucco G, Resegotti L. Early intensification followed by allogeneic BMT or autologous BMT or a second intensification in adult all: a randomised multicenter study. Leukemia 1992;6:204-8.
106. Diez Martin JL, Queipo de Llano, Llamas P, Regidor C, Cabrera Fores R. Treatment of high risk all (HRALL) in 1st CR with autologuous bone marrow transplantation (ABMT) or donor bone marrow transplant (BMT) or chemotherapy. A restrospective study. Proceedings of 20th European Group for Blood and Marrow Transplantation Meeting, Harrogate, UK, 13-17 March 1994.
107. Proctor SJ, Taylor PRA, Hamilton PJ. Acute lymphoblastic leukaemia in adults - an unselected, ten year, population based study of 180 cases assessing the role of early transplantation versus standard maintenance in different age cohorts. Br J Haematol 1994;87:42.
108. Yoshida T, Harada M, Funada H, Matue G, Shiobara S, Ishino C. Allogeneic bone marrow transplantation for the treatment of acute lymphoblastic leukemia. A comparison of bone marrow transplantation with conventional chemotherapy. Rinsho Ketsueki 1984;25:337-45.
109. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004;22:4075-86.
110. Horowitz MM, Messerer D, Hoelzer D, Gale RP, Neiss A, Atkinson A, et al. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med 1991;115:13-18.
111. Oh G, Gale R, Zhang MJ. Chemotherapy vs HLAidentical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. Bone Marrow Transplant 1998;22:253-7.
112. Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002;16:1259-66.
113. Gupta V, Yi Q-L, Brandwein J, Minden MD, Schuh AC, Wells RA, et al. The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison. Bone Marrow Transplant 2004;33:397-404.
114. Ueda T, Miyawaki S, Asou N, Kuraishi Y, Hiraoka A, Kuriyama K, et al. Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group. Int J Hematol 1998;68:279-89.
115. Dombret H, Gabert J, Boiron JM, Rigal H, Blaise D, Thomas X, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. Blood 2002;100:2357-66.
116. Hunault M, Harousseau J-L, Delain M, Truchan-Graczyk M, Cahn J-Y, Witz F, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: A GOELAMS trial. Blood 2004;104:3028-37.
117. Labar B, Suciu S, Zittoun R, Muus P, Marie JP, Fillet G, et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients 50 years old in first complete remission: results of the EORTC ALL-3 trial. Haematologica 2004;89:809-17.
118. Ribera JM, Oriol A, Bethencourt C, Parody R, Hernandez-Rivas JM, Moreno MJ, et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 2005;90:1346-56.
119. Nemet D, Labar B, Bogdanic V, Mrsic M, Skodlar J, Petrovecki M. ABMT versus chemotherapy as consolidation of acute leukaemia in first remission - a prospective single-centre study. Bone Marrow Transplant 1995;15:S55.
120. Fiere D, Leverger G, Sebban C, Boucheix C, Gisselbrecht C, Vernant JP, et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1993;11:1990-2001.
121. Chessells J, Bailey C, Wheeler K, Richards SM. Bone marrow transplantation for high-risk childhood lymphoblastic leukaemia in first remission: experience in MRC UKALL X. Lancet 1992;340:565-8.
122. Schaison G, Bordigoni P, Leblanc T, Lamagnere J-P, Baruchel A. Comparison of bone marrow transplantation (BMT), autologous BMT (ABMT), augmented chemotherapy (AC), in first complete remission in children with very increased risk acute lymphoblastic leukemias (VIRCALL). Proc Annu Meet Am Soc Clin Oncol 1993;12:A1043.
123. Saarinen-Pihkala UM, Mellander L, Nysom K, Ringden O, Schroder H, Glomstein A. Allogeneic bone marrow transplantation in first remission for children with very high-risk acute lymphoblastic leukemia: a retrospective case-control study in the Nordic countries. Nordic Society for Pediatric Hematology and Oncology. Bone Marrow Transplant 1996;17:357-63.
124. Wheeler KA, Richards SM, Bailey CC, Gibson B, Hann IM, Hill FGH, et al. Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: results from Medical Research Council UKALL X and XI. Blood 2000;96:2412-18.
125. Arico M, Valsecchi M, Camitta B, Schrappe M, Chessells J, Baruchel A, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998-1006
126. Uderzo C, Valsecchi M, Balduzzi A, Dini G, Miniero R, Locatelli F, et al. Allogeneic bone marrow transplantation versus chemotherapy in high-risk childhood acute lymphoblastic leukaemia in first remission. Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) and the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol 1997;96:387-94.
127. Sharathkumar A, Saunders EF, Dror Y, Grant R, Greenberg M, Weitzman S, et al. Allogeneic bone marrow transplantation vs chemotherapy for children with Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 2004;33:39-45.
128. Johnson FL, Thomas ED, Clark BS, Chard RL, Hartmann JR, Storb R. A comparison of marrow transplantation with chemotherapy for children with acute lymphoblastic leukemia in second or subsequent remission. N Engl J Med 1981;305:846-51.
129. Boulad F, Steinherz PG, Reyes B, Gillio AP, Small T, Kernan N. Allogeneic bone marrow transplantation (BMT) vs chemotherapy for the treatment of childhood acute lymphoblastic leukemia (ALL) in second remission (CR2): the MSKCC experience. Blood 1994;84(Suppl. 1):251a.
130. Chessells J, Rogers DW, Leiper AD, Blacklock H, Plowman PN, Richards S. Bonemarrow transplantation has a limited role in prolonging second marrow remission in childhood lymphoblastic leukaemia. Lancet 1986;1:1239-41.
131. Hanis R, Feig S, Coccia P, Warkentin P, Wiley F, Lampkin B, et al. ALL in second complete remission - a CCSG study of maintenance chemotherapy vs marrow transplantation. In Gale RP, Champhin RE, editors. Progress in Bone Marrow Transplantation. New York, NY: Liss; 1987. pp. 91-95.
132. Torres A, Martinez F, Gomez P, Fornés G, Rojas R, Herrera C, et al. Allogeneic bone marrow transplantation versus chemotherapy in the treatment of childhood acute lymphoblastic leukemia in second complete remission. Bone Marrow Transplant 1989;4:609-12.
133. Uderzo C, Valsecchi MG, Bacigalupo A, Meloni G, Messina C, Polchi P. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten year experience of the Italian Bone Marrow Transplantation Grup and the Italian Pediatric Hematoogy Oncology Association. J Clin Oncol 21995;13:352-8.
134. Ringden O, Bolme P, Lonnqvist B, Gustafsson G, Kreuger A. Allogeneic bone marrow transplantation versus chemotherapy in children with acute leukemia in Sweden. Bone Marrow Transplant 1989;6:137-44.
135. Hoogerbrugge PM, Gerritsen EJ, Van der Does-Van den Berg A, Van der Berg H, Zwinderman AH, Hermans J, et al. Case-control analysis of allogeneic bone marrow transplantation versus maintenance chemotherapy for relapsed ALL in children. Bone Marrow Transplant 1995;15:255-9.
136. Barrett AJ, Horowitz M, Pollock BH, Zhang MJ, Bortin MM, Buchanan GR. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lympho-blastic leukemia in a second remission. N Engl J Med 1994;331:1253-8.
137. Frassoni F, Bacigalupo A, Van Lint MT, Congui M, Carekham A, Martinengo M. Bone marrow transplantation versus chemotherapy for patients under 15 years of age in 2nd remission acute lymphoblastic leukaemia (ALL). Exp Hematol 1985;13(Suppl. 17):41.
138. Bacigalupo A, Van-Lint MT, Frassoni F, Occhini D, Pittaluga PA. Allogeneic bone marrow transplantation versus chemotherapy for childhood acute lymphoblastic leukaemia in second remission. Bone Marrow Transplant 1986;1:75-80.
139. Dopfer R, Henze G, Bender Gotze C, Ebell W, Ehninger G. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to teh BFM-and CoALL-protocols: results of the German Cooperative Study. Blood 1991;78:2780-4.
140. Wheeler K, Bailey C, Chessells J, Richards S. Comparison of bone marrow transplant and chemotherapy treatment for relapsed childhood acute lymphoblastic leukaemia (ALL). Exp Hematol 1996;24:A241.
141. Wheeler K, Richards S, Bailey C, Chessells J. Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: The MRC UKALL X experience. Br J Haematol 1998;101:94-103.
142. Harrison G, Richards S, Lawson S, Darbyshire P, Pinkerton R, Stevens R, et al. Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. Ann Oncol 2000;11:999-1006.
143. Schroeder H, Gustaffson G, Saarinen-Pihkala UM, Glomstein A, Jonmundsson G, Nysom K, et al. Allogeneic bone marrow transplantation in second remission of childhood acute lymphoblasticleukemia: a population-based case control study from the Nordic countries. Bone Marrow Transplant 1999;23:555-60.
144. Borgmann A, Hartmann R, Schmid H, Klingebiel T, Ebell W, Göbel U, et al. Isolated extramedullary relapse in children with acute lynphoblastic leukemia: a comparison between treatment results of chemotherapy and bone marrow transplantation. BFM Relapse Study Group. Bone Marrow Transplant 1995;15:515-21.
145. Borgmann A, Von SA, Hartmann R, Ebell W, Klingebiel T, Peters C, et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 2003;101:3835-9.
146. Messina C, Valsecchi M, Aricò M, Locatelli F, Rossetti F, Rondelli R, et al. Autologous bone marrow transplantation for treatment of isolated central nervous system relapse of childhood acute lymphoblastic leukemia. AIEOP/FONOP-TMO group. Associazione Italia Emato-Oncologia Pediatrica. Bone Marrow Transplant 1998;21:9-14.
147. Boulad F, Steinherz P, Reyes B, Heller G, Gillio AP, Small TN, et al. Allogeneic bone marrow transplantation (BMT) versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. J Clin Oncol 1999;17:197-207.
148. Feig S, Harris R, Sather H. Bone marrow transplantation versus chemotherapy for maintenance of second remission of childhood acute lymphoblastic leukemia: a study of the Children's Cancer Group (CCG-1884). Med Pediatr Oncol 1997;29:534-40.
149. Borgmann A, Schmid H, Hartmann R, Baumgarten E, Hermann K, Klingebiel T. Autologous bone-marrow transplants compared with chemotherapy for children with acute lymphoblastic leukaemia in a second remission: a matched-pair analysis. Lancet 1995;346:873-6.
150. Reiffers J, Labopin M, Sanz M. Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis. Bone Marrow Transplant 2000;25:1115-19.
151. Sirohi B, Powles R, Kulkarni S. Reassessing autotransplantation for acute myeloid leukaemia in first remission - a matched pair analysis of autologous marrow vs peripheral blood stem cells. Bone Marrow Transplant 2004;33:1209-14.
152. Vey N, Bouabdallah R, Stoppa A. Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6 year follow up study of 101 patients from a single institution. Bone Marrow Transplant 2004;33:177-82.
153. Garderet L, Labopin M, Gorin N-C. Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. Bone Marrow Transplant 2003;31:23-9.
154. Ringden O, Labopin M, Bacigalupo A. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002;20:4655-64.
155. Matsuzaki A, Eguchi H, Ikuno Y, Ayukawa H, Yanai F, Ishii E, et al. Treatment of childhood acute myelogenous leukemia with allogeneic and autologous stem cell transplantation during the first remission: a report from the Kyushu-Yamaguchi Children's Cancer Study group in Japan. Pediatr Hematol Oncol 2000;17:623-34.
156. Anak S, Saribeyoglu ET, Bilgen H, Unuvar A, Karakas Z, Devecioglu O, et al. Allogeneic versus autologous versus peripheral stem cell transplantation in CR1 pediatric AML patients: a single center experience. Pediatr Blood Cancer 2005;44:654-9.
157. Powles R, Mehta J, Singhal S, Horton C, Tait D, Milan S, et al. Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 cases from a single centre. Bone Marrow Transplant 1995;16:241-7.
158. Tiley C, Powles R, Treleaven J, Catovsky D, Milan S, Teo CP, et al. Feasibility and efficacy of maintenance chemotherapy following autologous bone marrow transplantation for first remission acute lymphoblastic leukemia. Bone Marrow Transplant 1993;12:449-55.
159. Mehta J, Powles R, Singhal S, Horton C, Tait D, Treleaven J, et al. Melphalan-total body irradiation and autoglogous bone marrow transplantation in adult acute leukemia beyond first remission. Bone Marrow Transplant 1996;18(Suppl. 2):119-23.
160. Ringdén O, Labopin M, Tura S, Arcese W, Iriondo A, Zittoun R, et al. A comparison of busulphan verus total body irradiation combined with cyclophosphamide as conditioning forleukemia: a population-based case control study from the Nordic countries. Bone Marrow Transplant 1999;23:555-60.
161. Ball ED, Wilson J, Phelps V, Neudorf S. Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow up. Bone Marrow Transplant 2000;25:823-9.
162. Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood 1992;79:2578-82.
163. Ringden O, Remberger M, Ruutu T, Nikoskelainen J, Volin L, Vindelov L, et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Blood 1999;93:2196-201.
164. Farag SS, Bolwell BJ, Elder PJ, Kalaycio M, Lin T, Pohlman B, et al. High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia. Bone Marrow Transplant 2005;35:653-61.
165. Resbeut M, Cowen D, Blaise D, Gluckman E, Cosset JM, Rio B, et al. Fractionated or single-dose total body irradiation in 171 acute myeloblastic leukemias in first complete remission: is there a best choice? Int J Radiat Oncol Biol Phys 1995;31:509-17.
166. Litzow MR, Perez WS, Klein JP, Bolwell BJ, Camitta B, Copelan EA, et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclo-phosphamide conditioning regimens for acute myelogeneous leukaemia in first remission. Br J Haematol 2002;119:1115-24.
167. Bacigalupo A, Vitale V, Corvo R, Barra S, Lamparelli T, Gualandi F, et al. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol 2000;108:99-104.
168. Schaap N, Schattenberg A, Bar B, Preijers F, Geurts van Kessel A, van der Maazen R, et al. Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen. Br J Haematol 1997;98:750-9.
169. Michel G, Gluckman E, Esperou-Bourdeau H, Reiffers J, Pico JL, Bordigoni P, et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation - a report from the societe Francaise de Greffe de Moelle. J Clin Oncol 1994;12:1217-22.
170. Ayas M, Al-Seraihi A, Al-Mahr M, Al-Jefri A, Belgaumi A, Elhassan I, et al. The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen. Pediatr Blood Cancer 2006;47:926-30.
171. Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant 2003;32:543-8.
172. Davies SM, Ramsay NKC, Klein JP, Weisdorf DJ, Bolwell B, Cahn JY, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000;18:340-7.
173. Weisdorf D, Woods W, Nesbit ME Jr, Uckun F, Dusenbery K, Kim T, et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome. Br J Haematol 1994;86:62-9.
174. Carpenter P, Marshall G, Giri N, Vowels M, Russell S. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan. Bone Marrow Transplant 1996;18:489-94.
175. Granados E, de la Camara R, Madero L, Diaz MA, Martin-Regueira P, Steegmann JL, et al. Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long-term event-free survival with conditioning regimens containing total body irradiation. Haematologica 2000;85:1060-7.
176. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced intensity conditioning: the role of dose intensity. Leukemia 2006;20:322-8.
177. Aoudjhane M, Labopin M, Gorin N-C, Shimoni A, Ruutu T, Kolb HJ, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneichaematopoietic stem cell transplantation for pateints older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (AWLP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005;19:2304-12.
178. Kroger N, Zabelina T, Sonnenberg S, Kruger W, Renges H, Stute N, et al. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditionng for stem cell transplantation in patients with acute myeloid leukemia. Bone Marrow Transplant 2000;26:711-16.
179. Miller CB, Rowlings PA, Zhang MJ, Jones RJ, Piantadosi S, Keating A, et al. The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. Exp Hematol 2001;29:1336-46.
180. Gorin N, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990;75:1606-14.
181. Chao NJ, Stein A, Long GD, Negrin RS, Amylon MD, Wong RM, et al. Busulfan/etoposide - initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood 1993;81:319-23.
182. Granena A, Castellsague X, Badell I, Ferra C, Ortega JJ, Brunet S, et al. Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement. Bone Marrow Transplant 1999;24:621-7.
183. Garcia J, Punti C, Picon M, Tigues D, Amill B, Canals C, et al. Bone marrow purging in acute lymphoblastic leukemia: biological and clinical features. J Hematother 1994;3:203-11.
184. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3 year disease free survival in recipients of unrelated donor bone marrow (T-cell depleted trial): a multi centre, randomised phase II-II trial. Lancet 2005;366:733-41.
185. Hale G, Zhang MJ, Bunjes D, Prentice HG, Spence D, Horowitz MM, et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graftversus- host disease and graft rejection. Blood 1998;92:4581-90.
186. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991;78:2120-30.
187. Thomas X, Le QH, Belhabri A, Chelghoum Y, Charrin C, Fiere D, et al. Allogeneic bone marrow tranplantation for young adult patients with newly diagnosed acute myeloid leukemia: HLAmatched sibling donor availability does not improve treatment outcome. Hematology Cell Therapy 2000;42:119-29.
188. Brunet S, Esteve J, Berlanga J, Ribera JM, Bueno J, Marti JM, et al. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy. Haematologica 2004;89:940-9.
189. Willemze R, Suciu S, Mandelli F, De WT, Labar B, Marie J, et al. High dose cytosine arabinoside (HDAraC) vs standard dose AraC (SD-AraC) during induction, and stem cell transplantation followed by IL-2 or no maintenance in acute myelogenous leukemia (AML): first report on the AML-12 phase III trial of the EORTC-Leukemia Group (LG) and GIMEMA. Blood 2005;106(Suppl.):83a, abstract 271.
190. Lioure B, Pigneux A, Recher C, Witz F, Lamy T, Fegueux N, et al. No benefit of adding high-dose melphalan (HDM) suppported by autologous stem cell transplantation (SCT) over treatment with conventional induction, HD ARAC consolidation, and auto SCT (busulfan + HDM) for acute myelogenous leukemia (AML) under 60: first results of the randomized AML 2001 trial. Blood 2006;108:183-4.
191. Lioure B, Delaunay J, Blaise D, Milpied N, Guardiola P, Cahn JY, et al. Allogeneic stem cell transplantation (SCT) with non myeloablative conditioning regimen (NST) following intensive consolidation may be equivalent to conventional alloSCT and superior to autoSCT for patients over 50 with acute myeloid leukemia (AML) in 1stCR: first results of the AML 2001 trial. Blood 2006;108:99.
192. Sakamaki H, Miyawaki S, Ohtake S, Emi N, Yagasaki F, Mitani K, et al. Allogeneic stem cell transplantation (allogeneic SCT) in adults with acute myelogenous leukemia (AML). final analysis of JALSG AML97 study. Blood (ASH Annual Meeting Abstracts) 2008;112:347.
193. Ganser A, Krauter J, Hoelzer D, Ottmann O, Martin H, Lubbert M, et al. Prospective randomized comparison of high dose AraC and autologous peripheral blood stem cell transplantation as lateconsolidation for patients 60 years with standard risk AML. Blood 2005;106(Suppl.):48a, abstract 151.
194. Burnett AK. A trial of directed therapy in younger patients with acute myeloid leukaemia: MRC AML 15. URL: http://www.controlled-trials.com/ISRCTN17161961/(accessed 9 February 2010).
195. Medical Research Council. Medical Research Council Working Party on Leukaemia in Adults Acute Myeloid Leukaemia Trial 12 (AML 12 AD). URL: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=679 (accessed 9 February 2010).
196. Brune M. Reduced intensity conditioning transplantation vs standard of care in acute myeloid leukemia. URL: http://clinicaltrials.gov/ct2/show/NCT00342316(accessed 9 February 2010).
197. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009;301:2349-61.
198. Ganser A, Krauter J, Hoelzer D, Ottmann O, Martin H, Lübbert M, et al. Late consolidation for patients with standard risk AML up to 60 years: results of a prospective randomized comparison of high dose AraC and autologous PBSCT. Blood 2004;104:45.
199. Heil G, Krauter J, Hoelzer D, Ottmann O, Martin H, Lübbert M, et al. Randomized comparison of autologous peripheral blood stem cell transplantation and high dose araC as late consolidation in adults with standard risk acute myeloid leukemia aged 60 years: results of a prospective multicenter trial. Onkologie 2004;27(Suppl. 3):81-2.
200. Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol 2005;23:482-93.
201. Ganser A. Treatment of adults aged up to 60 years with de novo acute myeloblastic leukaemia, secondary AML, or RAEB-T. URL: http://clinicaltrials.gov/ct2/show/NCT00209833 (accessed 10 March 2010).
202. Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A, et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. Leukemia 2000;14:1006-13.
203. Vignetti M, Andrizzi C. Acute myelogenous leukemia after relapse: bone marrow transplantation or immunotherapy with interleukin-2 - results of a GIMEMA-AIEOP prospective study. Bone Marrow Transplant 1997;19(Suppl.):S144.
204. Stevens R, Hann I, Wheatley K, Gray R. Improved outcome in pediatric acute myeloid leukemia (AML): results of the United Kingdom Medical Research Council (MRC) AML10 trial. Am Soc Clin Oncol 1995;14:1036.
205. Kardos G, Zwaan CM, Kaspers GJ, de-Graaf SS, de Bont ES, Postma A, et al. Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. Leukemia 2005;19:2063-71.
206. Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005;19:2130-8.
207. Creutzig U, Ritter J, Zimmermann M, Klingebiel T. Comparison of allogeneic matched related stem cell transplantation in 1st CR with chemotherapy alone in children with high risk AML. Annals of Hematology 2000;79(Suppl. 2):S14.
208. Stine K, Becton D, Van Houten DG, Ravindranath Y, Raimondi SC, Behm FG. Genetic randomization to allogeneic bone marrow transplant in first remission pediatric acute myeloid leukemia patients, Pediatric Oncology Group 9421 (now Children's Oncology Group). Blood 2004;104:178a.
209. Hasle H. NOPHO-AML 2004 Study for children with acute myeloid leukemia. URL: http://www.clinicaltrial.gov/ct2/show/NCT00476541 (accessed 10 February 2010).
210. Webb DK, Wheatley K, Harrison G, Stevens RF, Hann IM, Webb DK, et al. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia 1999;13:25-31.
211. Cornelissen JJ, van der Holt B, Verhoef GE, van't Veer MB, van Oers MH, Schouten HC, et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood 2009;113:1375-82.
212. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantationin first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALLXII/ECOG E2993). Blood 2008;111:1827-33.
213. Bassan R, Pogliani E, Casula P, Rossi G, Fabris P, Morandi S, et al. Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in highrisk groups. Hematology J 2001;2:117-26.
214. Labar B, Suciu S, Muus P, Willemze R, Marie JP, Fillet G, et al. Stem cell transplantation in ALL: a donor versus no donor comparison in the EORTC ALL-4 study. Leuk Res 2007;31(Suppl. 2):S15-16.
215. Hoelzer D. German multicenter trial for treatment of newly diagnosed acute lymphoblastic leukemia in adults (07/2003). URL: http://clinicaltrials.gov/ct2/show/NCT00198991 (accessed 10 March 2010).
216. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106:3760-7.
217. Lazarus HM, Richards SM, Chopra R, Litzow MR, Burnett AK, Wiernik PH, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 2006;108:465-72.
218. Tavernier E, Boiron J-M, Huguet F, Bradstock K, Vey N, Kovacsovics T, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukaemia initially treated by the LALA-94 trial. Leukemia 2007;21:1907-14.
219. Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol 2006;24:5742-9.
220. Balduzzi A, Valsecchi MG, Uderzo C, De LP, Klingebiel T, Peters C, et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 2005;366:635-42.
221. Ribera JM, Ortega JJ, Oriol A, Bastida P, Calvo C, Perez-Hurtado JM, et al. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial. J Clin Oncol 2007;25:16-24.
222. Pieters R, Schrappe M. Different therapies in treating infants with newly diagnosed acute leukemia. URL: http://clinicaltrials.gov/ct2/show/NCT00550992 (accessed 10 March 2010).
223. Gaynon PS, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Hawks R, et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. J Clin Oncol 2006;24:3150-6.
224. Torres A, Alvarez MA, Sanchez J, Flores R, Martinez F, Gomez P, et al. Allogeneic bone marrow transplantation vs chemotherapy for the treatment of childhood acute lymphoblastic leukaemia in second complete remission (revisited 10 years on). Bone Marrow Transplant 1999;23:1257-60.
225. Henze G. ALL-REZ BFM 2002: multi-center study for children with relapsed acute lymphoblastic leukemia. URL: http://clinicaltrials.gov/ct2/show/NCT00114348 (accessed 10 March 2010).
226. Lawson SE, Harrison G, Richards S, Oakhill A, Stevens R, Eden OB, et al. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the Medical Research Council UKALLR1 study. Br J Haematol 2000;108:531-43.
227. Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with earlystage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 2000;18:537-46.
228. Cornelissen JJ, Van der HB, Petersen EJ, Vindelov L, Russel CA, Hoglund M, et al. A randomized multicenter comparison of CD34+- selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies. Exp Hematol 2003;31:855-64.
229. Mahmoud HK, Fahmy OA, Kamel A, Kamel M, El-Haddad A, El-Kadi D. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 1999;24:355-8.
230. Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006;108:4288-90.
231. Skodlar J, Petrovecki M, Sucic M, Batinic D, Marusic M, Nemet D, et al. Autologous peripheral blood cells enhance hematopoietic recovery after autologous bone marrow transplantation: a randomized prospective study in patients with hematological malignancies. Croatian Med J 1997;38:19-24.
232. Remberger M, Ringden O. Similar outcome after unrelated allogeneic peripheral blood stem cell transplantation compared with bone marrow in children and adolescents. Transplantation 2007;84:551-4.
233. De Witte TM, Keating S, Suciu S, Zittoun R, Mandelli F, Amadori S. The value of autologous PSCT versus autologous BMT for patients with AML in first CR and impact of mobilized numbers of CD34-cells on outcome: final results of the randomized AML-10 trial of the EORTC LG and GIMEMA. Blood 2003;102:739a.
234. Friedrichs B, Tichelli A, Arat M, Schmitz N, Socie G. Long-term outcomes and late effects from the randomised trial comparing filgrastim-mobilised peripheral blood progenitor cells versus bone marrow transplantation for treating leukaemia. A study from the EBMT Late Effect Working Party. Bone Marrow Transplant 2008;41:S33.
235. Russell JA, Larratt L, Brown C, Turner AR, Chaudhry A, Booth K, et al. Sibling transplants for AML and MDS: influence of stem cell source on outcome. Bone Marrow Transplant 1999;23(Suppl. 1):S8.
236. Couban S, Lipton JH. Sibling donor peripheral stem cell transplant or sibling donor bone marrow transplant in treating patients with hematologic cancers or other diseases. URL: http://clinicaltrials.gov/ct2/show/NCT00438958 (accessed 10 March 2010).
237. Vaughan W, Nademanee A, Ball E, Wingard J, Waller E, Silverman M, et al. Comparing peripheral blood stem cell transplantation versus bone marrow transplantation in individuals with hematologic cancers (BMT CTN 0201). URL: http://clinicaltrials.gov/ct2/show/NCT00075816 (accessed 10 March 2010).
238. Grupp SA, Frangoul H. Donor bone marrow transplant with or without G-CSF in treating young patients with hematologic cancer or other diseases. URL: http://clinicaltrials.gov/ct2/show/NCT00450450 (accessed 10 March 2010).
239. Keating S, Suciu S, Mandelli F, De WT, Willemze R, Archimbaud E, et al. Autologous BMT or PSCT for patients with AML in first CR: a preliminary analysis of the AML 10 study of Leukemia Cooperative Group of the EORTC and GIMENA. Blood 1997;90(Suppl. 1):235a.
240. Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood 2007;109:1322-30.
241. Ringden O, Remberger M, Ruutu T, Nikoskelainen J, Volin L, Vindelov L, et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Blood 1999;93:2196-201.
242. Blaise D, Maraninchi D, Michallet M, Reiffers J, Devergie A, Jouet JP, et al. BusCy (120) versus CyTBI to prepare allo BMT for CR1 AML: a followup of a study from the GEGMO. Bone Marrow Transplant 1999;23(Suppl. 1):S71.
243. McCarthy PL. High-dose chemotherapy with or without total-body irradiation followed by autologous stem cell transplant in treating patients with hematologic cancer or solid tumors. URL: http://clinicaltrials.gov/ct2/show/NCT00536601 (accessed 10 March 2010).
244. Cordonnier C. Randomised prospective comparison of the NMA allograft and the traditional allograft in acute myeloid leukaemia. URL: http://clinicaltrials.gov/ct2/show/NCT00224614 (accessed 10 March 2010).
245. Scott BL. Chemotherapy with or without total-body irradiation in treating patients who are undergoing donor stem cell transplant for myelodysplastic syndromes or acute myeloid leukemia. URL: http://clinicaltrials.gov/ct2/show/NCT00322101 (accessed 10 March 2010).
246. Beelen DW. Clinical phase III trial treosulfan-based conditioning versus reduced-intensity conditioning (RIC). URL: http://clinicaltrials.gov/ct2/show/NCT00822393 (accessed 10 March 2010).
247. Bassan R. A remission induction therapy and risk-oriented postremission strategy for adultacute myelogenous leukemia (AML). URL: http://clinicaltrials.gov/ct2/show/NCT00495287 (accessed 10 March 2010).
248. Redaelli A, Botteman MF, Stephens JM, Brandt S, Pashos CL, Redaelli A, et al. Economic burden of acute myeloid leukemia: a literature review. Cancer Treat Rev 2004;30:237-47.
249. Ngamkiatphaisan S, Sriratanaban J, Kamolratanakul P, Intragumtornchai T, Noppakun N, Jongudomsuk P. Cost analysis of hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia at King Chulalongkorn Memorial Hospital. J Med Assoc Thailand 2007;90:2565-73.
250. Yu YB, Gau JP, You JY, Chern HH, Chau WK, Tzeng CH, et al. Cost-effectiveness of postremission intensive therapy in patients with acute leukemia. Ann Oncol 2007;18:529-34.
251. Cordonnier C, Maury S, Esperou H, Pautas C, Beaune J, Rodet M, et al. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant 2005;36:649-54.
252. van Agthoven AM, Groot MT, Verdonck LF, Lowenberg B, Schattenberg AV, Oudshoorn M, et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant 2002;30:243-51.
253. Uyl-de Groot CA, Hartog JGD, Huijgens PC, Willemze R, Van Ineveld BM. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands. J Hematother Stem Cell Res 2001;10:187-92.
254. Schwarzenbach F, Woronoff-Lemsi MC, Deconinck E, Jacquet M, Herve P, Cahn JY. Cost analysis of allogeneic bone marrow transplantation. Hematol Cell Ther 2000;42:149-54.
255. Barr R, Furlong W, Henwood J, Feeny D, Wegener J, Walker I, et al. Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol 1996;14:1413-20.
256. Dufoir T, Saux M-C, Terraza B, Marit G, Guessard S, Foulon G, et al. Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. Bone Marrow Transplant 1992;10:323-9.
257. Welch HG, Larson EB. Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 1989;321:807-12.
258. Viens-Bitker C, Fery-Lemonnier E, Blum-Boisgard C, Cordonnier C, Rochant H, Fischer A, et al. Cost of allogeneic bone marrow transplantation in four diseases. Health Policy 1989;12:309-17.
259. Kay HEM, Lawler SD, Powles RL, Clink HM. Cost of bone-marrow transplants in acute myeloid leukaemia. Lancet 1980;1:1067-9.
260. Uyl-de Groot CA, Okhuijsen SY, Hagenbeek A, Huijgens PC, Van Imhoff GW, Lowenberg B, et al. Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in the Netherlands. Bone Marrow Transplant 1995;15:605-10.
261. Armitage JO, Klassen LW, Burns CP, Kugler JW, Ray TL, Gingrich RD, et al. A comparison of bone marrow transplantation with maintenance chemotherapy for patients with acute nonlymphoblastic leukemia in first complete remission. Am J Clin Oncol 1984;7:273-8.
262. Madero L, Vicent MG, Ramirez M, Quintero V, Benito A, Diaz MA. Clinical and economic comparison of allogeneic peripheral blood progenitor cell and bone marrow transplantation for acute lymphoblastic leukemia in children. Bone Marrow Transplant 2000;26:269-73.
263. Costa V, McGregor M, Laneuville P, Brophy JM. The cost-effectiveness of stem cell transplantations from unrelated donors in adult patients with acute leukemia. Value Health 2007;10:247-55.
264. Faucher C, Fortanier C, Viens P, Le Corroller AG, Chabannon C, Camerlo J, et al. Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation). Bone Marrow Transplant 1998;21(Suppl. 3):S92-8.
265. Viens-Bitker C, Blum C, Bessis M, Cordonnier C, Rochant H, Jolly D, et al. [Calculation of direct standard costs in the evaluation of new technologies: application to the treatment of acute myeloblastic leukemias.] Revue Epidemiol Sante Publique 1986;34:41-51.
266. Corker RL. The cost effectiveness of bone marrow transplantation relative to consolidation chemotherapy for acute myelogenous leukemia patients in first remission. Diss Abstr Int B 1989;50:515.
267. Masaoka T. Medical cost of acute leukemia treatment bone marrow transplantation and chemotherapy. Exp Hematol 1994;22:680.
268. Aulesa C, Olive T, Bastida P, Ortega JJ. Cost assessment of two treatment modalities for acute non lymphoblastic leukaemia in children: prolonged sequential polychemotherapy versus short intensification chemotherapy followed by allogeneic or autologous bone marrow transplant. Biologia Clinica Hematologica 1992;14:221-8.
269. Rollinson DH, Rollinson DH. The cost of marrow transplantation compared with the cost of conventional treatment for acute leukaemia and aplastic anaemia. N Z Med J 1982;95:310-11.
270. Le Corroller AG, Faucher C, Auperin A, Blaise D, Fortanier C, Benhamou E, et al. Autologous peripheral blood progenitor-cell transplantation versus autologous bone marrow transplantation for adults and children with nonleukaemic malignant disease. Pharmacoeconomics 1997;11:454-63.
271. de Arriba F, Heras I, del Carmen Garcia M, Moraleda JM, Funes C, Ferrer F, et al. Coste economico del autotrasplante de progenitores hematopoyeticos. Med Clin Barc 1996;106:329-32.
272. Julia A, Bueno J, Gadea N, Massuet L, del Bano C. Estudio economico del coste del autotrasplante de precursores hematopoyeticos de sangre periferica comparado con el de medula osea. Med Clin Barc 1995;105:131-5.
273. Tennvall GR, Persson U, Nilsson B. The economic costs of acute myeloid leukemia in Sweden. Int J Technol Assess Health Care 1994;10:683-94.
274. Stalfelt AM, Brodin H, Stalfelt AM, Brodin H. Costs over time in conventional treatment of acute myeloid leukaemia. A study exploring changes in treatment strategies over two decades. J Intern Med 1994;236:401-9.
275. Lee SJ, Klar N, Weeks JC, Antin JH. Predicting costs of stemcell transplantation. J Clin Oncol 2000;18:64-71.
276. Wagner ND, Quinones VW. Allogeneic peripheral blood stem cell transplantation: clinical overview and nursing implications. Oncol Nurs Forum 1998;25:1049-55.
277. Bennett CL, Waters TM, Stinson TJ, Almagor O, Pavletic ZS, Tarantolo SR, et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;24:555-60.
278. Beard ME, Inder AB, Allen JR, et al. The costs and benefits of bone marrow transplantation. N Z Med J 1991;104:303-5.
279. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. URL: www.nice.org.uk/aboutnice/howwework/devnicetech/technologyappraisalprocessguides/ guidetothemethodsoftechnologyappraisal. jsp?domedia=1&mid=B52851A3-19B9-E0B5- D48284D172BD8459 (accessed 10 March 2010).
280. Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Services Res Policy 2009;9:110-18.
281. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
282. Andronis L, Barton P, Bryan S. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health Technol Assess 2009;13(29).
283. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
284. Wheatley K, Gray R. Commentary: Mendelian randomization - an update on its use to evaluate allogeneic stem cell transplantation in leukemia. Int J Epidemiol 2004;33:15-17.
285. Sierra J, Brunet S, Grañena A, Olivé T, Bueno J, Ribera JM, et al. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation. J Clin Oncol 1996;14:1353-63.
286. Cassileth PA, Anderson J, Lazarus HM, Colvin OM, Bennett JM, Stadtmauer EA, et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol 1993;11:314-19.
287. Mitus AJ, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C, et al. Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 1995;13:560-9.
288. Ortega J, Diaz de Heredia C, Olivé T, Bastida P, Llort A, Armadans L, et al. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy. Heamatologica 2003;88:290-9.
289. O'Brien TA, Russell SJ, Vowels MR, Oswald CM, Tiedemann K, Shaw PJ, et al. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group. Blood 2002;100:2708-16.
290. Woods W, Kobrinsky N, Buckley J, Neudorf S, Sanders J, Miller L, et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Children's Cancer Group pilot study. J Clin Oncol 1993;11:1448-57.
291. Berger M, Ferrero I, Vassallo E, Gastaldo L, Carraro F, Biasin E, et al. Stem cell transplantation as consolidation therapy for children in firstremission AML: a single-center report. Pediatr Hematol Oncol 2005;22:597-608.
292. Gorin N, Labopin M, Fouillard L, Meloni G, Frassoni F, Iriondo A, et al. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996;18:111-17.
293. Matsuyama T, Horibe K, Kato K, Kojima SS. Bone marrow transplantation for children with acute myelogenous leukaemia in the first complete remission. Eur J Cancer 2000;36:368-75.
294. Pession A, Rondelli R, Paolucci P, Pastore G, Dini G, Bonetti F, et al. Hematopoietic stem cell transplantation in childhood: report from the bone marrow transplantation group of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Haematologica 2000;85:638-46.
295. Aladjidi N, Auvrignon A, Leblanc T, Perel Y, Bénard A, Bordigoni P, et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 2003;21:4377-85.
296. Ifrah N, Witz F, Jouet JP, Francois S, Lamy T, Linassier C, et al. Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. GOELAMS Group. Cancer 1999;86:1496-505.
297. Annaloro C, Curioni ACE, Molteni M. Della Volpe A, Soligo D, Cortelezzi A, et al. Hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: a single-center analysis. Leuk Lymphoma 2004;45:1175-80.
298. Attal M, Blaise D, Marit G, Payen C, Michallet M, Vernaut JP, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autogous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1995;86:1619-28.
299. Blaise D, Gaspard M, Stoppa A, Michel G, Gastaut JA, Lepeu G, et al. Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant 1990;5:7-12.
300. Sotomayor EM, Piantadosi S, Miller CB, Karp JE, Jones RJ, Rowley SD, et al. Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy. Leuk Res 2002;26:461-71.
301. Arnold R, Beelen D, Bornhaeuser M, Bunjes D, Finke J, Kroeger N, et al. Stem cell transplantation in elderly patients with acute lymphoblastic leukemia (ALL) in first complete remission (CR1). Blood (ASH Annual Meeting Abstracts) 2008;112:1966.
302. Lee S, Min C-K, Kim D-W, Lee J-W, Kim Y-J, Park E-J. Allogeneic versus autologous hemopoietic stem cell transplantation for adults with high-risk acute lymphoblastic leukemia in first remission: a single center experience (1994-1999). Blood 2000;96:356b.
303. Mrsic M, Labar B, Nemet D, Bogdanic V, Radman I, Golubic-Cepulic B, et al. Stem cell transplants versus chemotherapy in the treatment of acute lymphoblastic leukaemia. Hematology J 2000;1(Suppl. 1):202.
304. Kröger N, Krüger W, Wacker-Backhaus G, Hegewisch-Becker S, Stockschläder M, Fuchs N, et al. Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1998;22:1029-33.
305. Stockschläder M, Hegewisch-Becker S, Krüger W, tom Dieck A, Mross K, Hoffknecht M, et al. Bone marrow transplantation for Philadelphiachromosome- positive acute lymphoblastic leukemia. Bone Marrow Transplant 1995;16:663-7.
306. Soiffer R, Roy D, Gonin R, Murray C, Anderson KC, Freedman AS, et al. Monoclonal antibody-purged autologous bone marrow transplantation in adultswith acute lymphoblastic leukemia at high risk of relapse. Bone Marrow Transplant 1993;12:243-51.
307. Martino R, Bellido M, Brunet S, Sureda A, Peyret M, Guardia R, et al. Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia. Bone Marrow Transplant 1998;21:1023-7.
308. Martino R, Bellido M, Brunet S, Altes A, Sureda A, Guardia R, et al. Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial. Haematologica 1999;84:505-10.
309. Dunlop L, Powles R, Singhal S, Treleaven JG, Swansbury GJ, Meller S, et al. Bone marrow transplantation for Philadelphia chromosomepositive acute lymphoblastic leukemia. Bone Marrow Transplant 1996;17:365-9.
310. Woods W, Ramsay N, Weisdorf D, Haake R, Vallera DA, Kim TH, et al. Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens. Bone Marrow Transplant 1990;6:9-16.
311. Giona F, Testi AM, Rondelli R, Amadori S, Arcese W, Meloni G, et al. ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse. Br J Haematol 1997;99:671-7.
312. Sandler ES, Homans A, Mandell L, Amylon M, Wall DA, Devidas M, et al. Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia: a pediatric oncology group pilot feasibility study. J Pediatr Hematol Oncol 2006;28:210-15.